Tislelizumab Combined With XELOX as Perioperative Therapy for Locally Advanced Gastric Cancer
Status:
Active, not recruiting
Trial end date:
2026-07-18
Target enrollment:
Participant gender:
Summary
The effective treatment of locally advanced gastric cancer has always been a research hotspot
in academia. In recent years, mainstream studies have shown that the treatment mode of
locally advanced gastric cancer has changed from single surgery mode in the past, to
multi-disciplinary comprehensive treatment mode for now, which is based on surgery. Several
studies indicate that for most late-stage LAGC, the perioperative treatment model can further
enhance the survival rates and prognosis of patients, compared with the combination of
standard radical resection and postoperative adjuvant chemotherapy. According to The Chinese
Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of
gastric cancer (Wang et al , 2021), neoadjuvant therapy and adjuvant therapy are recommended
for patients with locally advanced gastric cancer with clinical stage of cT3-4a N+ M0.
However, there is still a lack of unified standards and norms for precise preoperative
staging of gastric cancer, applicable population of neoadjuvant along with adjuvant therapy,
and the selection of treatment regimens. Therefore, this project is aimed to carry out a
single-arm, open-label, phase II clinical trial to administer tirelizumab plus XELOX for
perioperative management of resectable LAGC patients, and further explore the safety and
therapeutic effect of chemotherapy together with tirelizumab in the perioperative period of
LAGC, eventually, providing a new option for the perioperative treatment of LAGC.